Evidence map›Paper›PMID 40770600›Full record

ArticleReproductive sciences (Thousand Oaks, Calif.)2025

Luteinizing Hormone Preserves Oocyte-Granulosa Cell Communication in Growing Follicles Exposed to Chemotherapy with Alkylating Agents at the Primordial Stage in a Mouse Model.

Luis Miguel Del Castillo, Noelia Ramírez-Martín, María José Soriano, Jessica Martínez, Nuria Pellicer, Antonio Pellicer, Sonia Herraiz

Abstract read
PubMed Publisher
In one paragraph

Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luis Miguel Del Castillo *Department of Pediatrics, Obstetrics and Gynecology, School of Medicine, University of Valencia, 46010, Valencia, Spain.
Noelia Ramírez-Martín *IVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe), 46026, Valencia, Spain.
María José SorianoIVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe), 46026, Valencia, Spain.
Jessica MartínezIVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe), 46026, Valencia, Spain.
Nuria PellicerIVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe), 46026, Valencia, Spain.
Antonio PellicerIVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe), 46026, Valencia, Spain.
Sonia HerraizIVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe), 46026, Valencia, Spain. Sonia.Herraiz@ivirma.com.ORCID 0000-0003-0703-6922

Funding

Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana CIPROM/2021/058Instituto de Salud Carlos III CP19/00141Instituto de Salud Carlos III FI17/00264Ministerio de Ciencia, Innovación y Universidades FPU16/05264Ministerio de Ciencia, Innovación y Universidades FPU19/04926
6 · The paper itself

Abstract

Reciprocal communication between the oocyte and adjacent granulosa cells (GC) throughout folliculogenesis can be disrupted by chemotherapy. Recent work suggests that luteinizing hormone (LH) may protect the quality of metaphase-II oocytes derived from primordial follicles exposed to chemotherapy in mice. Here, we showed that LH improved the follicular yield of CD1 mice ovaries exposed to alkylating chemotherapy by primarily protecting the smallest follicles, i.e., the primordial and primary populations. LH treatment reverted the chemotherapy-induced impairment of oocyte-GC communication at the gene and protein levels in secondary and later-stage follicles exposed to alkylating chemotherapy at the primordial phase by preserving the germ and somatic cell compartments. These changes are follicle-specific, as supported by the absence of differences in ovarian stroma. LH also restored the immunofluorescence signal for cell junction proteins Cx37, E-Cad and Cx43, and for oocyte-secreted factors GDF9 and BMP15. The alteration of signal intensity associated with these cell junction proteins and oocyte-secreted factors by chemotherapy was detected beyond the secondary stage, suggesting that attenuation of oocyte-GC crosstalk might happen during the primary-secondary transition. Our results suggest that LH-treated primordial follicles retain the ability to properly establish oocyte-GC interactions and crosstalk during follicular growth representing a novel mechanism triggered by LH that would explain the reported protective effects of LH on oocyte quality and female fertility. However, this is an animal model study that should be validated in larger studies with human samples.

Indexed as

Antineoplastic Agents, AlkylatingCell CommunicationGranulosa CellsLuteinizing HormoneOocytesOvarian FollicleAnimalsBone Morphogenetic Protein 15Connexin 43FemaleGrowth Differentiation Factor 9MiceAntineoplastic Agents, AlkylatingBone Morphogenetic Protein 15Connexin 43Gdf9 protein, mouseGJA1 protein, mouseGrowth Differentiation Factor 9Luteinizing HormoneChemotherapyFertility PreservationFollicle DevelopmentFolliculogenesisLuteinizing HormoneSomatic–germ Cell Interactions

Identifiers

PMID40770600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.